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ABSTRACT 
 
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated 
transcription factor which belongs to the nuclear receptor superfamily and regulates 
gene transcription by heterodimerizing with retinoic X receptor (RXR). PPARα has 
attracted considerable attention since it was demonstrated to be pivotal regulators of 
lipoprotein metabolism, vascular inflammation, atherosclerosis and carcinogenesis. To 
date, studies addressing the regulation of human PPARα gene expression remain largely 
unexplored. In order to understand the structure and molecular mechanisms governing 
PPARα regulation, it is vital to identify and characterise the 5’-untranslated region 
(UTR) and promoter region of the human PPARα gene. In this study, six alternatively 
spliced variants and two new novel exons at the 5’-UTR of human PPARα gene were 
identified. The putative transcriptional start site of each variant was identified, leading 
to the discovery of four promoters in the human PPARα gene which are responsible for 
transcribing these alternatively spliced variants. Three of these four promoters, named 
promoter B, promoter C and promoter D, were successfully cloned and sequenced. 
Sequence analysis revealed potential binding sites for transcriptional factors AP-1, AP-
2, Sp1, STAT, C/EBP, GATA, CREB and Oct-1. In addition, TATA boxes were found 
in promoters C and D. However, no TATA boxes but several GC boxes were found 
within the first 100 nucleotides upstream of the transcriptional start site of promoter B. 
Finally, transient transfections using luciferase reporter constructs into HepG2 and 
Hep3B cells showed that both promoter B and promoter C are functional promoters, 
with promoter B being the more potent and stronger promoter. Deletion analysis of the 
human PPARα promoters identified a possible negative regulatory element located 
between the regions -765 to -1147 of promoter B and -413 to -967 of promoter C.  
 xviii
 xix
ABSTRAK 
 
Reseptor Aktivasi Pembiakan Peroksisom Alpha (PPARα) merupakan faktor transcripsi 
yang diaktifkan oleh ligan yang tergolong dalam superfamili reseptor nuklear dan 
mengawalatur transcripsi gen dengan bergabung dengan reseptor retinoik X (RXR). 
PPARα didapati berfungsi sebagai pengawaltur penting di dalam metabolisme lipid, 
inflamasi vaskular, aterosklerosis dan kanser. Sehingga kini, tidak banyak penyelidikan 
mengenai kawalatur gen PPARα telah dilakukan. Untuk memahami mekanisme 
molekul yang mengawalatur PPARα, adalah penting untuk mengenalpasti and 
mencirikan kawasan 5’-tak tertranslasi (UTR) dan kawasan promoter gen PPARα 
manusia. Daripada kajian ini, enam varian terbahagi alternatif dan dua exon baru pada 
bahagian 5’-UTR gen PPARα telah dikenalpasti. Tapak permulaan transkripsi putatif 
untuk setiap varian telah dikenalpasti dan seterusnya menghasilkan penemuan empat 
promoter PPARα yang bertanggungjawab mentranskripsikan enam varian terbahagi 
alternatif ini. Tiga daripada empat promoter PPARα, iaitu promoter B, promoter C dan 
promoter D telah diklonkan dan dijujukkan. Analisis jujukan menemui tapak pengikatan 
untuk faktor transkripsi AP-1, AP-2, Sp1, STAT, C/EBP, GATA, CREB dan Oct-1. 
Kotak TATA dijumpai pada promoter C dan D, tetapi tidak pada promoter B, yang 
sebaliknya mempunyai kotak GC pada lingkungan 100 nucleotida pertama daripada 
tapak permulaan transkripsi. Transfeksi (transien) dengan menggunakan konstruk 
pelapor lusiferase ke dalam sel HepG2 dan Hep3B membuktikan kedua-dua promoter B 
dan C adalah promoter berfungsi. Promoter B merupakan promoter yang lebih kuat dan 
berpotensi daripada promoter C. Analisis pemotongan kedua-dua promoter PPARα 
manusia mendapati kehadiran elemen pengawalatur negatif di antara bahagian -765 ke   
-1147 promoter B dan -713 ke -967 promoter C.  
INTRODUCTION 
1.1 Background 
Coronary heart disease is a major health problem and the leading cause of death 
in Malaysia. The link between cardiovascular disease and lipids has been appreciated 
for a long time. Cardiovascular disease is most often as a result of the damage occurring 
to the inside of the blood vessels through the formation of atherosclerosis. The build up 
of plaques begins as lipid underlays the endothelium of arteries, which in time, causes 
the narrowing of the vessels and severely limiting the blood flow in advanced cases. 
Rapture of plaque or thrombosis may lead to myocardial infarction or stroke (Berliner et 
al., 1995; Glass and Witztum, 2001; Vosper et al., 2002). 
 A family of transcription factors known as the Peroxisome Proliferator-
Activated Receptors (PPARs) plays a central role in regulating the lipid homeostasis 
and carbohydrate metabolism. The discovery of PPARs was highly significant and since 
then, the receptor has moved from the status of orphan receptor to one of the best 
characterised nuclear receptors. Their functional characterisation is providing unique 
insight into the role of fat in health and diseases. Recently, this nuclear receptor has also 
been shown to fulfil critical and unique roles in general transcriptional control of 
numerous cellular processes, with implications in inflammation control, atherosclerosis, 
cancer development and epidermal wound healing.  
 
1.2 Peroxisome Proliferator-Activated Receptors (PPARs) 
The peroxisome proliferator-activated receptors (PPARs) were discovered in the 
early 1990s by Issemann and Green (1990). PPARs are members of the superfamily of 
nuclear hormone receptors. There are three distinct PPAR subtypes - PPARα (also 
known as NR1C1), PPARβ (NR1C2) and PPARγ (NR1C3), each encoded by a separate 
 1
gene and each with a distinct tissue distribution pattern and metabolic functions 
(Issemann and Green, 1990; Braissant et al., 1996). PPARα is expressed preferentially 
in tissues exhibiting high catabolic rates of fatty acids, such as liver, kidney, heart and 
muscle (Auboeuf et al., 1997) and in cells of the arterial wall (Staels et al., 1998a). 
PPARβ is more general in terms of tissue distribution, with varying levels in different 
organs (Wahli, 2002), while PPARγ is expressed predominantly in adipose tissue and in 
the immune system (Fajas et al., 1997) (See Table 1.1). 
 The PPARs possess a domain structure common to other members of the nuclear 
receptor gene family (Figure 1.1). Sequence comparison of their DNA-binding domains 
(DBD) shows that they are highly conserved, while lower level of conservation is seen 
in the ligand-binding domains (LBD) across the subtypes (Willson et al., 2000). There 
is a significant sequence variation in the residues that line the ligand-binding pocket 
(Nolte et al., 1998; Uppenberg et al., 1998). The variation is responsible for 
determining the ligand selectivity and binding specificity of the PPAR subtypes (Xu et 
al., 2001). The NH3-terminal region of the receptor shows low sequence identity across 
the subtypes and is responsible for differences in the biological function of the subtypes 
(Castillo et al., 1999). 
 For years, PPARγ has been the most widely studied subtype. Recently, more 
interest has been generated into the other subtype named PPARα. PPARα has been 
proven to play pivotal role in fatty acid metabolism. Furthermore, PPARα has also been 
shown to mediate pleiotropic effects with direct implications on multiple fundamental 
pathways in the cell. 
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Table 1.1 Summary of PPAR subtypes and their tissue distribution 
 
 
       Subtype                                     Tissue distribution     
        PPARα     Liver, kidney, heart 
 
     PPARβ (or δ)         Ubiquitous 
 
        PPARγ             Adipose, immune cells 
 
 
 
 
 
 
 
 
 
             
                   hPPARα                                                                                                   LBD      DBD Ntrm 
                                         1           101          166      244              468 
 
                 hPPARγ 
                                         1            72            138    215              441 
 
           hPPARβ (or δ)                                                                                                                                  
    83%  
 
     68% 
    70%     86%  
                                         1         110            175    253               479    
 
Figure 1.1   Functional domains of the PPARs. Ntrm represents NH3-terminal; DBD 
represents DNA-binding domain; LBD represents ligand-binding domain. Numbers in 
bars represent the percent (%) amino acid identity between the human subtypes relative 
to PPARα. Numbers below each bar indicate the position of the last amino acid of each 
domain.                                                                                               
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1.3 Peroxisome Proliferator-Activated Receptor Alpha (PPARα) 
PPARα was the first PPAR to be identified (Issemann and Green, 1990). 
PPARα was originally cloned from a mouse liver cDNA library and has since been 
cloned from frogs, rats, guinea pigs and humans (Willson et al., 2000).  
PPARα tissue distribution in rodents and humans revealed high levels of mRNA 
in tissues, such as liver, heart, kidney and muscle (Table 1.1). In summary, regardless of 
species, the expression of PPARα correlates with high mitochondrial and peroxisomal 
β-oxidation activities. 
In mouse and rat, PPARα appears relatively late in development in tissues where 
it will be expressed in adulthood (Braissant and Wahli, 1998; Desvergne and Wahli, 
1999). In adult rat, relatively high levels of PPARα mRNA are detected in brown fat, 
liver, kidney, heart and the mucosa of stomach and duodenum. In addition, significant 
amounts of PPARα mRNA are also expressed in the retina, adrenal gland, skeletal 
muscle and pancreatic islets (Braissant and Wahli, 1998).  
Like rodents, human PPARα is highly expressed in the liver, heart, kidney, 
skeletal muscle and large intestine. However, the mRNA levels of PPARα in human 
liver appear lower than in the rodent liver (Palmer et al., 1998). In addition, it is 
expressed in steroidogenic tissues such as adrenals (Zhou and Waxman, 1998). 
Furthermore, human PPARα is also expressed in vascular cells including endothelial 
and smooth muscle cells and macrophages/foam cells (Staels et al., 1998a; Chinetti et 
al., 2000a; Neve et al., 2000). 
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1.4 PPARα: Mechanism of action 
Prior to transcriptional activation, PPARα heterodimerize with the retinoic X 
receptor (RXR) to form a complex (Kliewer et al., 1992). RXRs are also members of 
the nuclear hormone receptor superfamily that are activated following binding with 9 
cis-RA (9-cis retinoic acid) (Desvergne and Wahli, 1999). The PPARα/RXR complex 
then binds to a specific sequence in the 5’ end of the target genes, known as the 
peroxisome proliferator response element (PPRE).  
The PPRE was first characterised by using synthetic oligonucleotides (Kliewer 
et al., 1992) and consists of a direct repeat of two copies of a hexameric nucleotide 
sequence AGGTCA separated by one nucleotide, known as the DR-1 response elements 
(Tugwood et al., 1992). A PPARα-selective PPRE is further characterized by a 5’-
flanking C(C/G)(A/G)A(A/T)(C/T) consensus sequence. Conservation of this 5’-
flanking region is particularly essential for PPARα binding and therefore is an 
important determinant of the PPARα/RXR specificity (Issemann et al., 1993; Juge-
Aubry et al., 1997).  
PPARα/RXR heterodimer recognizes sequences situated within the DR-1 motif, 
whereby PPARα interacts with the upstream extended core hexamer of the DR-1, 
whereas RXR occupies the downstream motif (Palmer et al., 1995; IJpenberg et al., 
1997; DiRenzo et al., 1997) (Figure 1.2).  
Both the formation of PPARα/RXR heterodimer and the subsequent 
transcriptional activation of the target gene are ligand dependent. Ligand binding may 
evoke conformational changes within the DNA-binding domain, thereby altering the 
potential to stimulate transcription of target genes. Interaction of PPARα with RXR 
results in a permissive heterodimer, in which binding of 9-cis retinoic acid to RXR can 
alter activation as well (DiRenzo et al., 1997). 
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 Fibrates                             Eicosanoids 
                                                                                                    9 cis-RA  
 
 
 
 
  
 
 
                                                                         
                         C(C/G)(A/G)A(A/T)(C/T) AGGTCA(N)1 AGGTCA   Target gene 
                               PPRE                                       (DR-1)           
                                                                                           Nucleus 
 
 RXR   PPARα 
 
 
Figure 1.2 Mechanism of action of PPARα. Alteration of target gene transcription 
via binding of peroxisome proliferator response elements (PPRE) to the activated 
peroxisome proliferator-activated receptor alpha (PPARα) and the retinoic X receptor 
(RXR). 9 cis-RA represents 9 cis-retinoic acid; DR-1 represents the direct repeat of two 
copies of a hexameric nucleotide sequence AGGTCA separated by one nucleotide. 
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1.5  The structural organization of human PPARα gene 
The human PPARα has been mapped to chromosome 22q12-q13.1 by somatic 
cell hybridization and linkage analysis (Sher et al., 1993). As in the mouse, the human 
PPARα gene is composed of eight exons which spanned 83.7 kb, with a 5’-untranslated 
region encoded by exons 1, 2 and part of exon 3 (Figure 1.2) (Vohl et al., 2000). The 
coding region of PPARα comprises the remainder of exon 3 and exons 4-8, with the 3’-
untranslated region consisting of the last 232 bp of exon 8. The intron lengths vary 
between 1.4 kb to 24.8 kb as indicated in Figure 1.3 (Vohl et al., 2000).  
Recently, the number of exons which forms the PPARα gene was extended to 
ten exons due to the discovery of two new exons within the 5’-untranslated region of the 
PPARα gene (Pineda-Torra et al., 2002; GenBank Accession No. BC000052). These 
exons were named as Exons 1b and 2b, respectively, while the previously known Exon 
1 and 2 were named Exons 1a and 2a, respectively (Figure 1.4).  
Little research has been performed on the mRNA variants (isoforms) of PPARα, 
unlike the other PPAR subtype, the PPARγ, whose mRNA variants were determined in 
both human and mouse (Zhu et al., 1995, Fajas et al., 1998). In the human PPARγ, four 
mRNA variants were determined while two mRNA variants were identified in the 
mouse PPARγ, due to different promoter usage and alternative splicing (Zhu et al., 
1995, Fajas et al., 1998).  
In human PPARα, a splice mRNA variant which lacked the entire exon 6 was 
identified (Gervois et al., 1999). This deletion, due to alternative splicing, formed a 
truncated PPARα protein with dominant negative activity which interferes with the 
activity of the functional full-length PPARα protein (Gervois et al., 1999).  
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            Coding region 
1 2 3 4 5 6 7
  24.8 kb   21.5 kb   16.5 kb 
  2.9 kb   1.4 kb 
 11.8 kb 
8
  2.9 kb 
  83.7 kb  
Figure 1.3 Schematic representation of the human PPARα gene. The gene spans 
83.7 kb of genomic DNA. Upper panel represents the human PPARα messenger RNA. 
Arrows indicate translation start (methionine) and stop codons. The spatial localization 
of exons within the gene is shown in the lower panel. Exon numbers and the size of 
intron are also indicated.  
 
 
 
      1a     1b   2a   2b
  23 kb 
  600 bp 
   12 kb    10 kb 
            Coding region 
       3 
 
 
 
 
 
Figure 1.4 Schematic representation of the newly reported 5’ flanking region 
human PPARα gene. The upper panel represents the 5’-flanking region human mRNA. 
Arrow indicates the start codon (methionine). The lower panel represents the spatial 
localization of exons of the 5’ flanking region. The size of introns are indicated below 
the lower panel.   
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As with most members of the nuclear hormone superfamily, PPARα protein 
shares a common structure of five functional domains named A/B, C, D and E (Figure 
1.5). However, the F domain is absent from all PPARs compared with other members of 
the nuclear superfamily (Lazennec et al., 2000). The A/B domain (or the NH3-terminal) 
contains the ligand-independent transcription activation function 1 (AF-1) (Hi et al., 
1999). The C domain (or the DNA-binding domain) has a characteristic helix-loop-helix 
structure stabilized by two zinc atoms and is responsible for the binding to peroxisome 
proliferator response elements (PPREs) in the promoter region of target genes. The D 
domain is the hinge region that can modulate the DNA binding ability of the receptor 
and also involved in corepressor binding (Lazennec et al., 2000). The E domain (or 
COOH-terminal region) encompasses a ligand binding function and exhibits a strong 
ligand-dependent activation function (AF-2). The ligand binding domain facilitates the 
heterodimerization of PPARα with the retinoic X receptor (RXR). In its active state, 
this heterodimer is able to bind to a PPRE and modulate the expression of its target 
genes (Krey et al., 1997; Lazennec et al., 2000).         
   
                                                                         Dimerization interface 
                                                                                       NLS      
                               AF-1          NLS                                          AF-2 
 
             
                       1                             101         166      244                                   468 
       A/B              C       D         E           AD 
 
                                                 DBD                               LBD 
Figure 1.5 Structural and functional organization of the nuclear receptor 
PPARα protein. AD, activation domain; AF, activation function; DBD, DNA-binding 
domain; LBD, ligand-binding domain; NLS, nuclear localization signal. Numbers 
below each bar indicate the position of the last amino acid of each domain.      
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1.6 Ligands of PPARα 
PPARα is a ligand-activated transcription factor. The binding of ligands to the 
receptor greatly increases its transcriptional activity. A diverse range of compounds 
which include natural and synthetic substances serve as PPARα ligands, including fatty 
acids and fatty acid-derived products as well as pharmacological molecules such as 
plasticizers and herbicides (Issemann and Green, 1990; Krey at al., 1997; Forman et al., 
1997; Ward et al., 1998; Lin et al., 1999; Roberts-Thomson, 2000) (Table 1.2).  
 The ability of PPARα to bind such a diverse variety of natural and synthetic 
compounds has been puzzling. Partial explanation for this ability to bind to multiple 
ligands came with the description of the crystal structure of the ligand binding domain 
of PPARα. The ligand binding domain is made out of a three-dimensional fold, which 
consists of an antiparallel α-helical sandwich of 12 helices (Helix 1 to Helix 12) 
organised in three layers with a central ligand binding hydrophobic pocket (Bourguet et 
al., 1995; Xu et al., 2001; Wahli, 2002). Upon ligand binding, the ligand pocket closes 
and forms a “mouse trap model” (Wahli, 2002). The ligand binding pocket of PPARα is 
much larger than that of other nuclear receptors with a volume of approximately 
1300Å3, of which the ligand occupies only 30-40% (Xu et al., 2001; Wahli, 2002). 
Interestingly, Xu et al. (2001) identified the major determinant of selectivity of ligands 
in PPARα is the amino acid residue Tyr-314. This amino acid plays an important part in 
the transcriptional activation of PPARα receptor by ligands. 
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 Table 1.2 The peroxisome proliferator-activated receptor α (PPARα) 
activating ligands. PPARα is a ligand-activated transcription factor. The binding of 
ligands to the receptor greatly increases its transcriptional activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
        Class of compound                                     Name 
  
 
Fatty acids    Linoleic acid 
      Linolenic acid 
      Oleic acid 
      Arachidonic acid 
 
Eicosanoids    8(S)-Hydroxyeicosatetraenoic 
         Acid 
      Leukotriene B4 
  
Fibrates       Clofibric acids 
      Ciprofibrate 
      Gemfibrozil 
      4-Chloro-6-(2, 3-xylidino)-2- 
         pyrimidinlythioacetic 
              acid (Wy-14643) 
 
Plasticizers    Diethylhexylphthalate (DEHP) 
      Diethylhexyladipate (DEHA) 
 
 Herbicide    Lactofen 
      2, 4-Dichlorophenoxyacetic acid 
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1.6.1 Natural ligands of PPARα 
A range of saturated and unsaturated fatty acids could activate PPARα 
(Gottlicher et al., 1992; Willson et al., 2000). Palmitic acid, oleic acid, linoleic acid and 
arachidonic acid are examples of saturated acid that can activate PPARα (Banner et al., 
1993). Notably, PPARα is the only subtype that binds with high affinity to a wide range 
of saturated acids (Xu et al., 1999b). This may be due to the fact that the PPARα pocket 
is more lipophilic and less solvent compared to the other PPAR subtypes, explaining its 
selectivity for more lipophilic saturated fatty acids (Xu et al., 2001). 
Eicosanoids, a class of fatty acids mainly derived from arachidonic acid, are 
activators of PPARα. 8-S-hydroxyeicosatetraenoic acid (8S-HETE), a compound 
associated with inflammation, and leukotriene B4 (LTB4), a chemotactic inflammation 
mediator, are examples of eicosanoids that can activate PPARα (Yu et al., 1995; 
Devchand et al., 1996; Forman et al., 1997) (Figure 1.6). 
 
         
        palmitic acid                                           linoleic acid 
 
                                               
8(S)-HETE              
 
                     
Figure 1.6 Chemical structures of natural ligands of PPARα. Palmitic acid, 
linoleic acid and 8-S-hydroxyeicosatetraenoic acid (8S-HETE) are potent PPARα 
ligands. 
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1.6.2 Synthetic ligands of PPARα 
The hypolipidemic fibrates drugs are important class of PPARα ligands 
(Issemann and Green, 1990). Wy-14643, clofibric acid, ciprofibrate, fenofibrate and 
gemfibrozil are examples of fibrates that can activate PPARα. Clofibric acid and 
fenofibric acid are dual activators of PPARα and PPARγ, with 10-fold selectivity for 
PPARα. These fibrates are widely used in the treatment of hypertriglyceridemia and 
combined hyperlipidemia (Forman et al., 1997). Another compound known as 
ureidofibrates, such as GW 2331 and GW 9578, have been reported as potent and 
subtype-selective PPARα agonists with lipid lowering activity (Brown et al., 1999).  
Interestingly, certain non-steroidal anti-inflammatory drugs (NSAIDs), 
including indomethacin, fenoprofen, flufenamic and ibuprofen, have been shown to 
bind and activate PPARα at high micromolar concentrations, with fenoprofen activating 
the receptor to a degree comparable to that obtained with Wy-14643 (Lehmann et al., 
1997) (Figure 1.7).    
 
 
 
 
 
 
 
 
 
                                                                           
                         
                                   Wy-14643                                            clofibrate, R=Et 
                                                                                                clofibric acid, R=H                                
   Fenofibrate
              
Figure 1.7 Chemical structures of synthetic ligands of PPARα.  
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1.6.3 PPARα cofactors 
PPARα is modulated by cofactors that either enhance (coactivators) or silence 
(corepressor) its transcriptional activity (Xu et al., 1999a; Glass and Rosenfeld, 2000). 
Initially, it was thought that the cofactors simply bridge PPARα with basic 
transcriptional machinery. Recently, it has become clear that these cofactors carried out 
several enzymatic activities, suggesting the fact that they can control gene expression by 
specifically modifying chromatin and DNA structure (Dowell et al., 1997a, Glass et al., 
1997; Pazin and Kadonaga, 1997; Moras and Gronemeyer, 1998; Latchman, 1998).  
 Ligand binding induces a conformational change in the receptor that results in 
dissociation of corepressors and removal of histone deacetylases from DNA. 
Subsequently, coactivators’ complexes that contain proteins with histone 
acetyltransferase activity are recruited. Acetylation is associated with alteration of 
nucleosome structure, producing a more open chromatin structure to modulate 
accessibility of promoter regions, thereby increasing the transcription of target gene 
(Dowell et al., 1997a; Glass et al., 1997; Pazin and Kadonaga, 1997; Moras and 
Gronemeyer, 1998) (Figure 1.8).  
 Some of these cofactors identified include CREB binding protein (CBP/p300) 
and steroid receptor coactivator (SRC)-1, as well as PPAR-binding protein (PBP), 
PPAR-interacting protein (PRIP), peroxisomal trihydroxycoprostanoyl-CoA oxidase 
(THCOX), silencing mediator for retinoid and thyroid hormone receptors (SMRT) and 
nuclear receptor corepressor (NCoR).  
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  PPAR RXR
  HAT 
     CoA 
                                       Ligands  
 
 
 PPAR RXR 
      CoR 
 HDAC 
PPAR RXR
  Inactive state                                                                                       Active state 
 
Figure 1.8 Transcriptional activation of PPARα by cofactors. Transcriptional 
activity, in general, is activated with the release of corepressor (CoR) complexes, which 
contain histone deacetylase activity (HDAC), and the recruitment of coactivators (CoA), 
which target histone acetyl transferases (HAT) to the promoter. The differential docking 
of cofactors is facilitated by structural changes brought about by ligand-binding 
coreceptor phosphorylation.  
 
CBP/p300 is widely expressed (Chrivia et al., 1993; Janknecht and Hunter, 
1996; Misiti et al., 1998) and coactivates numerous transcription factors including 
several nuclear receptors (Chakravarti et al., 1996; Hanstein et al., 1996; Kamei et al., 
1996; Smith et al., 1996; Dowell et al., 1997b; Kraus and Kadonaga, 1998). CBP/p300 
are coactivators that exhibit histone acetyltransferase activity and also interact with 
another histone acetyltransferase known as P/CAF (Dowell et al., 1997b). 
Dowell et al. (1997b) demonstrated that 79 amino acids of p300-(39-117) and 
115 amino acids of CBP-(1-115) are sufficient for interaction with PPARα (Dowell et 
al., 1997b; Gelman et al., 1999). A LXXLL nuclear interaction motif, which is a 
signature motif for the binding of cofactor to nuclear receptors, has been identified 
within these regions (amino acids 81-85 of p300 and 69-73 of CBP) and this single 
motif is sufficient for interaction with PPARα (Dowell et al., 1997b). p300 interacts 
with PPARα through the amino acids within the COOH-terminal portion (amino acids 
448-468) (AF-2) as well as the residues within the hinge region known as the T-box of 
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the PPARα receptor (amino acids 166-179) (Dowell et al., 1997b). The constitutive 
presence of CBP/p300 could enhance the basal ligand independent transcriptional 
activity of PPARα in vivo and could thereby explain the high level of basal activity of 
PPARα. 
The steroid receptor coactivator (SRC)-1 is the first described nuclear receptor 
coactivator (Onate et al., 1995; Smith et al., 1996). SRC-1 has intrinsic histone acetyl 
transferase activity (Spencer et al., 1997) and is ubiquitously expressed (Onate et al., 
1995; Misiti et al., 1998). Two LXXLL motifs have been mapped in SRC-1. Its 
interaction with PPARα appears to be ligand-dependent. The AF-2 of the PPARα LBD 
serves as an adaptor surface for the interaction with SRC-1 (Nolte et al., 1998). The two 
LXXLL motifs of a single SRC-1 molecule interact separately with the AF-2 helix of 
each receptor molecule of a dimer, thus forming a stable ternary complex of two 
PPARα LBDs and one SRC-1 molecule (Nolte et al., 1998).   
The PPAR-binding protein (PBP) and the PPAR-interaction protein (PRIP) were 
isolated on the basis of its interaction with the LBD of PPARα in the yeast two-hybrid 
system (Zhu et al., 1997; Zhu et al., 2000). PBP and PRIP both contain two copies of 
the sequence motif LXXLL and their respective interaction with PPARα, coupled with 
the presence of a ligand, increase the transcriptional activity of the nuclear receptor. 
These two coactivators, which are devoid of histone acetyltransferase activities, appear 
to be involved in the second step of coactivation, which is to serve as facilitators linking 
the receptor complex to the basal transcriptional machinery (Zhu et al., 2000).   
The reason for the existence of a multitude of coactivators remains elusive. One 
possibility is that different coactivators may preferentially participate in the 
transcription of specific target genes. It is also possible that PPARα uses only distinct 
subset of coactivators for optimal transcriptional activity due to the differences in 
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peroxisome proliferator signalling and other complex cross-talk mechanisms (Zhu et al., 
2000). 
Most of these coactivators directly interact with the COOH-terminal portion of 
the ligand-binding domain (LBD) of the PPARα, which contains a ligand-dependent 
activation function (AF) motif AF-2 (Nolte et al., 1998; Glass and Rosenfeld, 2000). 
However, recently, another coactivator known as peroxisomal enoyl-CoA hydratase/3-
hydroxyacyl-CoA dehydrogenase (bifunctional enzyme, BFE) was identified as a strong 
interaction partner and activator of the NH3-terminal domain of PPARα which contains 
the ligand-independent activation function motif AF-1 (Juge-Aubry et al., 2001). The 
BFE is suggested to activate the basal transcriptional activity of PPARα by modulating 
the recruitment of proteins such as histone acetylases or other transactivating proteins 
(Juge-Aubry et al., 2001). Alternatively, it may mediate the activity of PPARα by 
modifying the intracellular import of PPARα into the nucleus (Juge-Aubry et al., 2001). 
Juge-Aubry et al. (2001) also suggested the possibility of BFE forming a ternary 
complex with PPARα and another peroxisomal enzyme, named peroxisomal 
trihydroxycoprostanoyl-CoA oxidase (THCOX), and therefore modulates the activity of 
PPARα through a novel peroxisomal-nuclear feed-forward loop. Interestingly, THCOX, 
which catalyses the first step of the peroxisomal oxidation of the CoA esters of bile acid 
intermediates, is also a coactivator of PPARα and interacts with the NH3-terminal of 
PPARα (Juge-Aubry et al., 2001). 
The silencer mediator for retinoid and thyroid hormone receptors (SMRT) and 
nuclear receptor coreceptor (NCoR) are corepressors identified using yeast two-hybrid 
system and are suggested to down-modulate PPARα-mediated gene transcription 
(Lavinsky et al., 1998; Dowell et al., 1999). It has been shown that NCoR, which 
couples with other proteins with histone deacetylase activities, binds to the receptor and 
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induce a more tightly packed chromatin structure (Latchman, 1998). These corepressors 
are ligand independent. Hence, the binding of ligand to PPARα induces it to release a 
corepressor complex with histone deacetylase activity and bind coactivators with 
histone acetylase activity. These coactivators produce a more open chromatin structure 
compatible with transcription. There has also been a speculation that the NCoR 
corepressor protein interacts with the NH3-terminal of PPARα and partially silent the 
activity of AF-1 domain, thus explaining the down-regulation of the PPARα gene 
expression (Juge-Aubry et al. 1999). 
 
1.7 Alternative pathways for PPARα transcriptional activation 
1.7.1 Activation by phosphorylation 
Ligand-dependent transcriptional activation by PPARα is mediated by a large, 
complex COOH-terminal domain that integrates several critical functions: ligand 
binding, dimerization, trans-activation and interaction with transcriptional coactivators 
(Glass et al., 1997).  
 Several nuclear hormone receptors, including PPARs, are regulated by 
phosphorylation in addition to ligand-dependent activation. PPARα was first shown to 
be a phosphoprotein in primary rat adipocytes in culture. Treatment of these cells with 
insulin increases the PPARα phosphorylation (Shalev et al., 1996).  
Juge-Aubry et al. (1999) demonstrated that the 1-92 amino acids (NH3-terminal) 
of PPARα contain AF-1 like trans-activation domain, which is further activated by 
insulin through pathways involving the mitogen-activated protein kinases (MAP-K) 
p42/p44 and the phosphorylation of two serine residues at positions 12 and 21 of 
PPARα (Juge-Aubry et al., 1999). The phosphorylation sites in PPARα are found to be 
highly conserved across species (Juge-Aubry et al., 1999).  
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The phosphorylation of the NH3-terminal of PPARα results in the dissociation 
of corepressor proteins, which may then result in a further transcriptional enhancement 
of this domain (Juge-Aubry et al., 1999).  
 Lazennec et al. (2000) demonstrated that phosphorylation of PPARα by protein 
kinase A (PKA) pathway is an important modulator of PPARα activity. A combination 
of PKA activators and PPARα ligands lead to the stabilization of the PPARα DNA 
binding, which in turn increases the transcriptional activity of PPARα (Lazennec et al., 
2000).  
However, phosphorylation has also been shown to inhibit the PPARα signalling 
pathway. For example, transcriptional activity of PPARα is inhibited up to 80% by 
growth hormone through the Janus kinase 2-signal transducer and activator of 
transcription 5b (JAK2-STAT5b) pathway (Zhou and Waxman, 1999b). STAT5b 
inhibits PPARα activity by directly interacting and phosphorylating the NH3-terminal of 
PPARα. However, the phosphorylation was shown to be independent from the MAP 
kinase phosphorylation of serine residues at positions 12 and 21 as in the case with 
insulin (Zhou and Waxman, 1999b).  
Therefore, the effect of phosphorylation on the PPARα signalling pathway, 
depending upon the nature of triggering signal, is suggested to involve specific 
pleiotropic actions or ‘cross-talking’ between different kinase pathways (Desvergne and 
Wahli, 1999).  
 
1.7.2 Activation of PPARα:RXR heterodimer by RXR agonists 
Another alternative activation pathway of PPARα:RXR heterodimer occurs 
through ligand binding to RXR. PPARα forms a permissive heterodimer with RXR, 
meaning that either partner can regulate the transcriptional activity of the DNA-bound 
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complex by interacting with its cognate ligand, on its own or when both partners are 
liganded (Desvergne and Wahli, 1999). Cotransfection studies have shown that both 
members of the PPARα:RXR complex can mediate a response in the presence of their 
respective ligand and cotreatment of cells with both ligands results in additive effects 
(Mangelsdorf et al., 1991; Kliewer et al., 1992; Gearing et al., 1993; Keller et al., 1993; 
Kersten et al., 1995; Desvergne and Wahli, 1999). 
RXR forms inactive tetramers in the absence of its ligands and addition of RXR-
specific ligands preferentially directs the formation of homodimers rather than 
heterodimers (Kersten et al., 1995). However, the specificity of action behind the 
formation of PPARα:RXR heterodimers rather than RXR homodimers remains 
undetermined (Mangelsdorf et al., 1991; Desvergne and Wahli, 1999).  
 
1.8 PPARα and lipoprotein metabolism 
1.8.1 PPARα and free fatty acid metabolism 
PPARα is highly expressed in tissues with elevated rates of fatty acid 
catabolism, where it regulates genes involved in fatty acid uptake, activation into acyl-
CoA esters, degradation via the peroxisomal and mitochondrial β-oxidation pathways 
and ketone synthesis (Schoonjans et al., 1996a; Chinetti et al., 2000a). 
 PPARα acts as regulator of intracellular fatty acid uptake controls.  Intracellular 
fatty acid concentrations are partly regulated by import and export system that is 
controlled by proteins such as fatty acid transport protein (FATP), fatty acid translocase 
(FAT/CD36) and Acyl-CoA synthetase (ACS), which facilitate the transport of fatty 
acids through the cell membrane and their esterification preventing their efflux 
(Abumrad et al., 1993; Martin et al., 1997; Tontonoz et al., 1998).   
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Treatment with PPARα agonists (activators) has been shown to induce fatty acid 
transport protein (FATP) mRNA levels in rat liver and intestine, and induced acyl-CoA 
synthetase (ACS) mRNA levels in liver and kidney (Martin et al., 1997; Motojima et 
al., 1998). The regulation of fatty acid transport protein and acyl-CoA synthetase 
expression by PPARα activators has been shown to occur at transcriptional level 
(Motojima et al., 1998; Fruchart et al., 1999). 
All these evidence show that PPARα activators influence fatty acid cellular 
uptake, which is a crucial regulatory step in lipid metabolism. Once inside the cells, 
fatty acid must penetrate into the mitochondrial where its metabolism takes place. 
Muscle-type carnitine palmitoyltransferase type I (CPT-I), a key enzyme in 
mitochondrial fatty acid catabolism, contains a PPRE in its promoter region and is 
regulated by PPARα activators (Brandt et al., 1998; Mascaro et al., 1998; Chinetti et 
al., 2000a).  
Mitochondrial 3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) synthase is a key 
enzyme in ketogenesis. HMG-CoA catalyses the condensation of acetyl-CoA and 
generates HMG-CoA, which is eventually converted into ketone bodies (Meertens et 
al., 1998). A PPRE was identified in the mitochondrial HMG-CoA gene and activation 
of PPARα was proven to up-regulate the gene expression of HMG-CoA (Meertens et 
al., 1998). These observations, taken together, indicate that PPARα controls fatty acid 
uptake, activation into acyl-CoA esters and degradation through the peroxisomal and 
mitochondrial β-oxidation pathways, and also the synthesis of ketones (Chinetti et al., 
2000a).  
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1.8.2 PPARα and triglyceride-rich lipoprotein metabolism  
 There is increasing evidence that serum triglycerides are strong risk factors in 
cardiovascular diseases. One of the major effects of PPARα activation on lipid 
metabolism is to reduce triglyceride-rich levels in plasma. PPARα activators alter the 
synthesis and the catabolism of the triglyceride-rich lipoproteins in a way that decreases 
plasma triglyceride levels via induction of the lipoprotein lipase (LPL) activity 
(Schoonjans et al., 1996b).  
Schoonjans et al. (1996b) demonstrated that PPARα mediates the triglyceride-
lowering action of PPARα activators by increasing lipoprotein lipase gene expression in 
a PPRE-mediated manner. A sequence element identified as a PPRE was found to be 
present in the human lipoprotein lipase promoter which was responsible in stimulating 
the expression of the gene. Two distinct mechanisms may be involved in PPARα 
induction of lipoprotein lipase activity: firstly, through the stimulation of the LPL gene 
expression and secondly, by the induction of hydrolytic activity of enzyme for 
triglyceride-rich lipoproteins secreted following treatment with PPARα activators 
(Fruchart et al., 1999). 
 Apolipoprotein CIII (Apo CIII) plays a key role in delaying the catabolism of 
triglyceride rich particles, by inhibiting their binding to the endothelial surface and 
lipolysis by LPL (Hertz et al., 1995; Staels et al., 1995; Desvergne and Wahli, 1999; 
Vosper et al., 2002). PPARα activators were also proven to decrease apolipoprotein 
CIII levels, thus resulting in an enhanced lipolytic activity (Hertz et al., 1995; Staels et 
al., 1995). A few mechanisms may be involved in this negative regulation. Firstly, 
PPARα activators may suppress Apo CIII by displacing the strong transcriptional 
activator of the apolipoprotein gene with a lesser active complex, resulting in lower Apo 
CIII promoter activity (Hertz et al., 1995). Secondly, there is a possibility that PPARα 
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activators indirectly decrease the expression of a strong transcriptional activator of the 
Apo CIII gene, i.e. the hepatocyte nuclear factor-4 (HNF-4) (Hertz et al., 1995). 
Alternatively, PPARα activators may induce the expression of repressor proteins of the 
Apo CIII gene, such as Apolipoprotein A-I regulatory protein-I, Ear3/COUP-TF or Rev-
erb-alpha (Vu-Dac et al., 1998). 
   
1.8.3 PPARα and high-density lipoprotein (HDL) metabolism  
High-Density Lipoprotein (HDL) metabolism plays important and protective 
role against cardiovascular diseases. HDL transports cholesterol to the liver for 
metabolism and excretion, resulting in reduced serum cholesterol availability (Barter 
and Rye, 1994; Vosper et al., 2002). PPARα activation by fibrates influences the 
expression of genes encoding for proteins involved in HDL metabolism by five key 
genes. These five key genes are apolipoprotein A-I, apolipoprotein A-II, lipoprotein 
lipase, scavenger receptor class B type I and adenosine triphosphate-binding cassette 
transporter-1. 
 
1.8.3.1 Apolipoprotein A-I and apolipoprotein A-II 
 Recent studies have demonstrated PPARα activation by fibrates increases 
plasma HDL concentrations through the induction of expression of the human 
Apolipoprotein A-I (Apo A-I) and Apolipoprotein A-II (Apo A-II) genes (Vu-Dac et 
al., 1994; Vu-Dac et al., 1995; Fruchart, 2001). PPARα directly influences the 
expression of human Apolipoprotein A-I and Apolipoprotein A-II genes. The 
transcription rate of the human Apo A-I gene was shown to be induced by PPARα 
which interacts with a positive PPRE located in the human Apo A-I gene promoter liver 
specific enhancer (Vu-Dac et al., 1994). PPARα was also shown to bind with high 
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affinity to a DR-I-type PPRE located in the human apolipoprotein A-II promoter, 
thereby activating apolipoprotein A-II gene transcription (Vu-Dac et al., 1995).  
 
1.8.3.2 Lipoprotein lipase 
 Activation of PPARα by fibrates induces lipoprotein lipase expression via 
transcriptional level in the liver, resulting in increased lipolysis (Schoonjans et al., 
1996b). Activated PPARα binds to PPRE in the human lipoprotein lipase gene 
promoter. An increase in lipolysis leads to an increase in pre-β-HDL, which is the key 
acceptor of cholesterol from peripheral cells during the process of reverse cholesterol 
transport (Fruchart, 2001).   
 
1.8.3.3 CD-36 and LIMPII analogous 1 (CLA-I)/scavenger receptor B type I (SR-
BI) 
 Scavenger receptor B type I (SR-BI) and its human homologue (CLA-I) are cell 
surface receptors. The roles played by SR-BI and CLA-I are to bind HDL with high 
affinity and mediate the selective uptake of cholesteryl esters from HDL in liver and 
steroidogenic tissues (Chinetti et al., 2000b; Fruchart, 2001). SR-BI promotes 
cholesterol removal from peripheral cells, including macrophages, thus suggesting that 
CLA-I/SR-BI may play a key role in reverse cholesterol transport pathway (Chinetti et 
al., 2000b; Fruchart, 2001). PPARα activation is seen to induce both CLA-I and SR-BI 
expressions (Fruchart, 2001; Chinetti et al., 2000b).  
 
1.8.3.4 Adenosine triphosphate-binding cassette transporter-1 (ABC-1)  
 ABC-1 plays pivotal role in HDL metabolism by exporting unesterified 
cholesterol and phospholipids from cells (Fruchart, 2001). PPARα activation induces  
